Mouse SAP Reference Standard
Cat.No. : | Apcs-57M |
Product Overview : | Serum was collected from mice of several strains, ages and both sexes. |
- Specification
- Gene Information
- Related Products
Species : | Mouse |
Form : | Liquid |
Usage : | For Research Use Only, NOT for Diagnostic Use. For In Vitro Use Only. Not for Human or Animal Consumption. |
Storage : | 4°C for short-term storage or frozen for long-term storage. |
Preservative : | 0.1% sodium azide |
Gene Name : | Apcs serum amyloid P-component [ Mus musculus ] |
Official Symbol : | Apcs |
Synonyms : | APCS; serum amyloid P-component; APCS amyloid P-component serum protein; Sap; |
Gene ID : | 20219 |
mRNA Refseq : | NM_011318 |
Protein Refseq : | NP_035448 |
UniProt ID : | P12246 |
Chromosome Location : | 1 H3; 1 80.33 cM |
Pathway : | Amyloids, organism-specific biosystem; Disease, organism-specific biosystem |
Function : | metal ion binding; sugar binding; |
Products Types
◆ Recombinant Protein | ||
Apcs-1658M | Recombinant Mouse Apcs Protein, Myc/DDK-tagged | +Inquiry |
Apcs-585M | Active Recombinant Mouse Apcs protein(Met1-Asp224), His-tagged | +Inquiry |
APCS-2311H | Recombinant Human APCS Protein, MYC/DDK-tagged | +Inquiry |
APCS-341H | Recombinant Human APCS Protein, MYC/DDK-tagged, C13 and N15-labeled | +Inquiry |
APCS-728M | Recombinant Mouse APCS Protein, His-tagged | +Inquiry |
◆ Native Protein | ||
APCS-8258H | Native Human Serum Amyloid P | +Inquiry |
APCS-31189TH | Native Human APCS | +Inquiry |
◆ Lysates | ||
APCS-3089MCL | Recombinant Mouse APCS cell lysate | +Inquiry |
APCS-1269HCL | Recombinant Human APCS cell lysate | +Inquiry |
APCS-1761RCL | Recombinant Rat APCS cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (20)
Ask a questionThe duration of use of therapy depends on the type of disease and treatment regimen, and needs to be carried out under the guidance of a professional physician.
The advantages and disadvantages of s versus other treatments need to be evaluated in the context of the specific disease and treatment regimen.
The specificity and specificity of s allow them to be used in precision medicine to achieve personalized treatment.
The stability of the is one of the important factors for its clinical application, and poor stability of the protein may lead to adverse reactions in patients or reduce the therapeutic effect.
Recombinant proteins, as exogenous proteins, may cause a response from the immune system, but there are already several techniques used to reduce their immunogenicity.
Recombinant proteins can be used in vaccine preparation, and there are already several vaccines based on s on the market.
The efficacy of s and traditional drugs depends on the type of disease and individual differences, and needs to be selected on a case-by-case basis.
Recombinant proteins can be used to treat a variety of diseases, such as immune deficiency diseases, tumors, cardiovascular diseases, etc.
Recombinant proteins usually need to be administered intravenously, but there are also some oral s that are currently being studied.
With the advancement of technology, the preparation of s has also been continuously improved, and large-scale production has become possible.
Any medical technology and drug treatment has a certain risk, is no exception, need to be reasonable application under the guidance of professional doctors.
The preparation of s is subject to compliance with relevant policies and regulations, particularly with regard to biosafety.
Recombinant protein therapy should follow the basic principles of individuality, pertinence, safety and effectiveness.
The pharmacokinetics and pharmacodynamics of s have been clearly understood, but they still need to be explored and perfected in clinical practice.
The production cost of is relatively high, but because of its therapeutic effect and broad application prospects, it has become an important field in the pharmaceutical industry.
The application of s needs to be adjusted individually according to the specific situation of the patient in order to achieve the optimal therapeutic effect.
Recombinant proteins have been used in the treatment of various neurological diseases, such as multiple sclerosis and Parkinson's disease.
As a new drug therapy technology, has broad application prospects, and more s may be used in the future.
Recombinant proteins are subject to various metabolic and decomposition influences in the body, and different proteins will have different stability and half-lives.
Clinical trials of s are subject to strict compliance with relevant ethical and regulatory requirements and are subject to regulatory approval and supervision.
Customer Reviews (4)
Write a reviewShort half-life and high clearance.
APCS produced by them has low preparation cost and high cost performance.
Stability of APCS is very good, and it can maintain stable performance even in extreme environments, which shows its excellent adaptability and reliability.
Production process is very much in line with the principle of green production.
Ask a Question for All Apcs Products
Required fields are marked with *
My Review for All Apcs Products
Required fields are marked with *
Inquiry Basket